A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects

Stopped early · Phase 1 · Has a placebo group

Conditions studied: Alzheimer's Disease

In brief

This is a first in human Phase 1 study in two parts with healthy volunteers receiving a single dose of PU AD in three small cohorts and a multiple ascending dose in two small cohorts.

Key facts

Study ID

NCT03935568

Run by

Samus Therapeutics, Inc.

People needed

40

Starts

2019-06-24

Expected to finish

2019-12-23

Last updated by the study team

2023-04-18

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or female (Women of non-child bearing potential)
• 18 to 60 years of age for part one, >/= 60 years of age for part two

You may not qualify if…

• Women of child bearing potential or Female with positive pregnancy test or who is lactating.
• History or presence of conditions, which in the judgment of the PI, are known to interfere with the absorption distribution, metabolism, or excretion of drugs.
• History or presence of conditions that may place the subject at increased risk as determined by the PI.
• Has taken other investigational drugs or participated in any clinical study within 30 days.
• Any other condition or prior therapy that, in the PI's opinion, would make the subject unsuitable for the study, or unable or unwilling to comply with the study procedures

Where it is running

• ICON Early Phase Services — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.